The 44 most recent market catalysts affecting $LLY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 85
Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact
Eli Lilly's FDA approval for Onswik, a once-weekly insulin, is a major positive development, offering a more convenient treatment option for type 2 diabetes patients and potentiall…
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 95
Eli Lilly shares are trading higher after the company announced FDA approval of its Onswik once-weekly insulin injection to treat Type 2 Diabetes.
The FDA approval of Eli Lilly's Onswik is a major corporate catalyst, directly boosting LLY shares due to the significant revenue potential of a once-weekly insulin injection for T…
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 55
Bill Ackman Calls AI’s Rare-Disease Breakthrough ‘Incredible’ After Model Finds Drug Combination for Dying Patient
Bill Ackman, through Pershing Square, highlighted a significant case where AI successfully identified a novel drug combination for a rare disease patient, leading to remission. Thi…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer
Eli Lilly's Inluriyo, in combination with Verzenio, has received full FDA approval for ESR1-mutated, ER+/HER2- locally advanced or metastatic breast cancer. This is a significant p…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week'
Eli Lilly's CEO, Dave Ricks, revealed that their new oral GLP-1 drug, Foundayo, is capturing a significant one-third of new oral GLP-1 patients, and their overall GLP-1 treatments …
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Breaks Ground On Houston Facility To Manufacture Active Pharmaceutical Ingredients For Medicines Like Foundayo; Site Will Employ More Than 600 People In High-Wage Jobs
Eli Lilly's groundbreaking on a $6.5 billion API manufacturing facility in Houston is a significant corporate development. This investment is part of a larger $50 billion push to r…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Announces FDA Approval Of Inluriyo In Combination With Verzenio For Treatment Of Adults With ER+, HER2–, ESR1-Mutated Locally Advanced Or Metastatic Breast Cancer
Eli Lilly announced that its drug Inluriyo, in combination with Verzenio, received full FDA approval for treating adults with ER+, HER2–, ESR1-mutated locally advanced or metastati…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Diabetes Drug Franchise Remains Strong, Analyst Praises Foundayo Trajectory
This filing details a positive analyst report from Guggenheim on Eli Lilly, highlighting the strength of its diabetes drug franchise, especially Foundayo. The analyst, Seamus Ferna…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Eli Lilly, Raises Price Target to $1284
Guggenheim analyst Seamus Fernandez has maintained a 'Buy' rating on Eli Lilly and raised the price target from $1273 to $1284. This action signals continued bullish sentiment from…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 85
Eli Lilly Stock Gains as Retatrutide and Foundayo Data Highlight Pipeline Strength
Eli Lilly announced positive late-stage clinical trial data for its key pipeline drugs, Retatrutide (obesity/type 2 diabetes) and Foundayo (cardiovascular events in diabetes), ahea…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Exec Speaking At Morgan Stanley Conference Says Company Now Has More Than 30% Share Of New Starts In Oral Obesity Treatment Market,
An Eli Lilly executive, speaking at a Morgan Stanley conference, revealed that the company has captured over 30% of new starts in the oral obesity treatment market. This is signifi…
Sep 8, 2026
Market Technicals
Bearish
Impact 55
Why Is Eli Lilly Stock Falling Tuesday?
Eli Lilly's 2% stock drop on Tuesday is attributed to a confluence of factors: a general 'risk-off' market environment, the healthcare sector being the weakest performer, and speci…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 75
FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
The FDA has disclosed receiving 990 adverse event reports for compounded semaglutide and over 730 for compounded tirzepatide, alongside establishing an import alert for unapproved …
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 65
Eli Lilly Says 52-Week Data from TOGETHER-PsO and TOGETHER-PsA Phase 3b trials of the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) Vs. Taltz Alone Shows Improved and Durable Efficacy in Patients With Psoriatic Disease and Obesity
Eli Lilly disclosed positive 52-week data from its TOGETHER-PsO and TOGETHER-PsA Phase 3b trials, demonstrating that the combination of Taltz and Zepbound maintained or further imp…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 95
Eli Lilly To Acquire Merida And Pay Up To $2.875B In Cash; Transaction Expected To Close In Q4 2026
Eli Lilly is acquiring Merida Biosciences for up to $2.875 billion, a move that significantly expands Lilly's presence in the immunology space. Merida's platform focuses on selecti…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Says FDA Approves Mounjaro, Dual GIP And GLP-1 Hormone Receptor Agonist, To Lower Risk Of Major Adverse Cardiovascular Events In Adults With Type 2 Diabetes
Eli Lilly's Mounjaro (tirzepatide) has received FDA approval to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes at high risk. This is a…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 75
Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs
Eli Lilly's announcement details a real-world study demonstrating that Zepbound (tirzepatide) significantly lowers overall healthcare expenses for older adults with obesity, primar…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 65
Eli Lilly Announces Results From Real-World Study Of Overweight Or Obese Adults Over 55 Indicating That Staying On Zepbound For Weight Management Lowered Healthcare Costs Over Time
Eli Lilly announced results from a real-world study showing that Zepbound, their weight management drug, significantly reduced healthcare costs for overweight or obese adults over …
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 55
Eli Lilly Makes Foundayo Available To Eligible UK Adults Privately, Seeks NICE Assessment For NHS Use At £100-£120 Pricing
Eli Lilly is strategically expanding the market for its osteoporosis drug, Foundayo, by first making it available privately in the UK. Concurrently, the company is pursuing a NICE …
Aug 19, 2026
Market Technicals
Neutral
Impact 55
Watching Eli Lilly; Hearing Investor Business Daily SwingTrader Buys Stock
The headline highlights a specific trading signal from Investor's Business Daily's SwingTrader, indicating a 'buy' on Eli Lilly. This is primarily a technical signal, suggesting sh…
Aug 13, 2026
Market Technicals
Neutral
Impact 65
Watching Eli Lilly; Hearing Investor Business Daily SwingTrader Sells Stock
This headline primarily reflects a technical trading signal from a recognized publication, Investor's Business Daily's SwingTrader. While not a fundamental shift in Eli Lilly's bus…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 65
Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities
Eli Lilly is taking strong legal and regulatory action against the illegal sale of its investigational drug, retatrutide, which is currently in Phase 3 trials for obesity and type …
Aug 12, 2026
Market Technicals
Neutral
Impact 55
Watching Eli Lilly; Hearing Investor Business Daily SwingTrader Buys Stock
The headline highlights a 'SwingTrader' buy signal for Eli Lilly from Investor's Business Daily. This is a technical indicator, not a fundamental change in the company's prospects,…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 75
Eli Lilly Filed Six New Lawsuits Against U.S. Entities Selling Black-Market Retatrutide
Eli Lilly's lawsuits are a significant corporate catalyst, directly impacting its future revenue potential for Retatrutide, a highly anticipated GLP-1 agonist. By aggressively targ…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $1376
Truist Securities analyst Robyn Karnauskas reaffirmed a 'Buy' rating for Eli Lilly and made a minor upward adjustment to its price target, moving it from $1370 to $1376. This actio…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1330
Wells Fargo analyst Mohit Bansal has maintained an 'Overweight' rating on Eli Lilly and raised the price target from $1280 to $1330. This action signals continued confidence in Eli…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1410
Cantor Fitzgerald analyst Carter Gould maintained an 'Overweight' rating on Eli Lilly and raised the price target from $1350 to $1410. This action reflects an analyst's updated val…
Aug 6, 2026
Market Technicals
Bullish
Impact 65
Dow Hits New All-Time High: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone
The Dow Jones Industrial Average surged to a new record high, primarily fueled by robust earnings reports from key companies like Eli Lilly, Disney, and Wynn Resorts, which all saw…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 95
Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion
Eli Lilly's Q2 2026 earnings report significantly exceeded Wall Street expectations, with adjusted EPS of $8.38 against an estimate of $6.01 and revenue of $22.97 billion against $…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 65
Eli Lilly CFO Says Expects Global Rollout Of Foundayo In All Major Markets In 2027
Eli Lilly's CFO provided an update on the anticipated global rollout of Foundayo, stating it is expected in all major markets in 2027. This is significant because Foundayo is a new…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
Eli Lilly CFO Says Injectable GLP-1 Drugs Remain Key Growth Driver, Account For Three Out Of Four New Patient Starts
Eli Lilly's CFO confirmed during a conference call that injectable GLP-1 drugs are the company's key growth driver, responsible for 75% of new patient starts. This is significant b…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 95
Eli Lilly shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance with its midpoint above estimates.
This headline represents a major corporate catalyst for Eli Lilly, indicating strong operational execution and a positive outlook for its product pipeline, particularly given the r…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 95
Eli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate
Eli Lilly reported Q2 adjusted earnings per share of $8.38, significantly beating the analyst consensus of $6.01 by 39.43%. Quarterly sales also exceeded expectations, coming in at…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 85
Eli Lilly Announces FDA Breakthrough Therapy Designation For Olomorasib Monotherapy In Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer, Second Such Designation For Drug
The FDA Breakthrough Therapy Designation for Olomorasib is a major positive for Eli Lilly, as it expedites the development and review of a drug for a high unmet medical need. This …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
Eli Lilly, Resilience Investing $750M To Expand Critical Medicines Manufacturing Capacity In U.S.
Eli Lilly and Resilience are investing $750 million to expand manufacturing capabilities for critical medicines, with a focus on Lilly's diabetes and obesity portfolio. This move i…
Jul 30, 2026
Market Technicals
Neutral
Impact 65
Watching Eli Lilly; Hearing Investor Business Daily SwingTrader Sells Stock
This headline highlights a technical signal from a well-known trading publication, Investor's Business Daily's SwingTrader. While not a fundamental change in Eli Lilly's business, …
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 85
Eli Lilly Reports Topline Results From TRIUMPH-2 And TRIUMPH-3 Phase 3 Trials Evaluating Retatrutide; Treatment Met Primary Endpoint, With Substantial Weight Loss In Adults With Obesity
Eli Lilly reported highly positive Phase 3 trial results for retatrutide, a novel triple hormone receptor agonist, showing significant weight loss and improved cardiometabolic mark…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 55
Eli Lilly On Novo Nordisk Lawsuit, Says "We Stand Firmly Behind Our Advertising"; We Will Continue To Focus On The Science And Defend Against Novo Nordisk Lawsuit Vigorously; Rather Than Compete On The Merits Of Its Products, Novo Is Asking Court To Stop Lilly From Communicating Results Of That Trial
Eli Lilly disclosed that it is being sued by Novo Nordisk over its advertising practices, with Lilly stating it will 'vigorously' defend itself. This legal dispute centers on the c…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Eli Lilly, Raises Price Target to $1600
Citigroup analyst Geoff Meacham maintained a 'Buy' rating on Eli Lilly and raised the price target from $1500 to $1600. This action signals strong analyst conviction in Eli Lilly's…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Bernstein Maintains Outperform on Eli Lilly, Raises Price Target to $1385
Bernstein analyst Courtney Breen has maintained an 'Outperform' rating on Eli Lilly and raised the price target from $1300 to $1385. This action signals continued bullish sentiment…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
UBS Maintains Buy on Eli Lilly, Raises Price Target to $1425
UBS analyst Michael Yee's decision to maintain a 'Buy' rating and significantly raise the price target for Eli Lilly (LLY) from $1250 to $1425 signals strong conviction in the comp…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 55
Guggenheim Maintains Buy on Eli Lilly, Lowers Price Target to $1273
Guggenheim analyst Seamus Fernandez maintained a 'Buy' rating on Eli Lilly and raised the price target from $1235 to $1273. This upward revision in the price target, despite the 'B…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.